Share on LinkedInShare on LinkedIn

ARTICLE · 30 JULY 2009

Pharmaceutical Patent Settlements Under Fire On Both Sides Of The Atlantic

Morrison Foerster
Morrison Foerster
Contributor
Morrison Foerster

Morrison Foerster

With approximately 1,000 lawyers in 19 offices, Morrison & Foerster is a preeminent global law firm...

View firm profile
Explore more from Morrison Foerster

In recent weeks, the pharmaceutical industry has been in the crosshairs of antitrust enforcers in the U.S. and in Europe.

United StatesIntellectual Property

In recent weeks, the pharmaceutical industry has been in the crosshairs of antitrust enforcers in the U.S. and in Europe.  Specifically, patent litigation settlements in which a brand pharmaceutical manufacturer makes a payment to a potential generic entrant in return for a delay of entry (so-called "reverse payment settlements") are under attack on both sides of the Atlantic. 

In the United States, reverse payment settlements now face attack on three fronts, at the Department of Justice ("DOJ"), the Federal Trade Commission ("FTC"), and in Congress.

  • The DOJ, under the new administration's leadership, recently argued in an amicus brief to the Second Circuit that reverse payment settlements are presumptively unlawful under Section 1 of the Sherman Antitrust Act.1  The DOJ's argument represents a change of course that aligns the DOJ's position on reverse payment settlements with that of the FTC.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from